Charles River Associates has picked up Justus Dehnen, who joins from QuintilesIMS Consulting Group. Dehnen takes on the role of Vice President of CRA’s the Life Sciences Practice based in Munich.
Prior to joining Charles River Associates, Justus Dehnen worked at QuintilesIMS Consulting Group, where he was briefly a Principal of Life Science Pricing and Market Access. He previously worked more broadly for the IMS Consulting Group for more than ten years, his most recent role was Country Principal Germany & Head of Pricing and Market Access Germany. Earlier in his career, between 2003 and 2006, he worked at Genmedics Biotechnology as its CEO; at Cell Consulting from 2001, as Managing Consultant/Senior Manager; at Accedo Networks (Hong Kong), from 2000, as Managing Director; and at Capgemini Consulting, from 1996, in his last role as a Senior Consultant.
Dehnen, who holds a Master's degree in Management & Organisation from the Universität Bayreuth, brings more than 20 years of experience, across pharma, biotech, and medical device companies. In his new role as Vice President of CRA’s the Life Sciences Practice based in Munich, he will leverage his specialised knowledge of pricing and market access, contracting, and loss of exclusivity (LoE) strategy for the firm’s national and international client base.
Commenting on the addition, CRA's President and Chief Executive Officer Paul Maleh, says, "Justus Dehnen’s expansive background in the European life sciences industry adds depth to CRA’s European life sciences offering. He has direct industry experience, as a former CEO of an international operating biotechnology company, as well as an extensive global consulting background on pricing and market access. We look forward to offering his expertise to clients.”